-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raise our target price to $18 from $17, 6.6x our 2027 EPS forecast, a discount to peers due to VTRS's slower growth prospects. We adjust our 2026 EPS estimate to $2.48 from $2.45 and maintain our 2027 EPS forecast at $2.72. Viatris reported a strong first quarter for 2026, with total revenues of $3.5B, up 4.7% Y/Y, above expectations, and adjusted EPS of $0.59. The Greater China segment was a standout performer, with revenue accelerating 18% Y/Y, significantly ahead of expectations. This was driven by favorable market fundamentals, strategic investments in selling and marketing, and a more than doubling of sales through e-commerce platforms. While the company raised its growth expectation for China for the full year from low-single digits to mid- to high-single digits, we think policy risks exist in a highly dynamic and unpredictable environment. Next, we see the upcoming U.S. launches of the weekly contraceptive patch XULANE LO and fast-acting meloxicam, to be a key focus to potentially accelerate growth.